Emerging Markets Earnings Roundup: J&J, Abbott And Roche (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Abbott moved to recover from recall and pricing issues for infant formula in China while Johnson & Johnson updated its device business and Roche reported strong growth in emerging markets.
You may also be interested in...
Roche Considers Moving Two Drugs Into Phase III, Drops Early-Stage Alzheimer’s Compound In Strong 3rd Quarter
Roche is moving into Phase III with a Lucentis successor, lampalizumab, in ophthalmology, but has dropped development of a Phase I BACE inhibitor for Alzheimer’s disease, the company announced during a third-quarter earnings update, which highlighted pipeline tweaks amid comparatively strong product sales.
J&J Opens Device R&D Center In China For Growing Rural Market
SHANGHAI - Johnson & Johnson and its device company in China Johnson & Johnson Medical (Suzhou) Ltd. will open a new innovation center in Suzhou to develop medical devices and diagnostic products for emerging markets in Asia
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.